Similar articles

• Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: subgroup analyses in the Scandinavian Simvastatin Survival Study.

  Haffner SM, Alexander CM, Cook TJ, Boccuzzi SJ, Musliner TA, Pedersen TR, Kjekshus J, Pyörälä K. Haffner SM, et al. Arch Intern Med. 1999 Dec 13-27;159(22):2661-7. doi: 10.1001/archinte.159.22.2661. Arch Intern Med. 1999. PMID: 10597756 Clinical Trial.
• Atorvastatin 10 mg plus ezetimibe 10mg compared with atorvastatin 20 mg: impact on the lipid profile in Japanese patients with abnormal glucose tolerance and coronary artery disease.

  Uemura Y, Watarai M, Ishii H, Koyasu M, Takemoto K, Yoshikawa D, Shibata R, Matsubara T, Murohara T. Uemura Y, et al. J Cardiol. 2012 Jan;59(1):50-6. doi: 10.1016/j.jjcc.2011.09.001. Epub 2011 Nov 17. J Cardiol. 2012. PMID: 22100058 Clinical Trial.
• Bimonthly update: lipidology. Therapy and clinical trials.

  Cater N, Jialal I. Cater N, et al. Curr Opin Lipidol. 1997 Dec;8(6):U88-9. doi: 10.1097/00041433-199712000-00016. Curr Opin Lipidol. 1997. PMID: 9440935 Review. No abstract available.
• High-dose atorvastatin therapy achieves 25% reduction in CV events in TNT substudy of diabetic patients.

  [No authors listed] [No authors listed] Cardiovasc J S Afr. 2006 Jul-Aug;17(4):206-7. Cardiovasc J S Afr. 2006. PMID: 17001426 No abstract available.
• Cholesterol lowering and coronary artery disease: mechanisms of risk reduction.

  Archbold RA, Timmis AD. Archbold RA, et al. Heart. 1998 Dec;80(6):543-7. doi: 10.1136/hrt.80.6.543. Heart. 1998. PMID: 10065020 Free PMC article. Review. No abstract available.